382 related articles for article (PubMed ID: 19755699)
21. Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study.
Hoffman RM; Lo M; Clark JA; Albertsen PC; Barry MJ; Goodman M; Penson DF; Stanford JL; Stroup AM; Hamilton AS
J Clin Oncol; 2017 Jul; 35(20):2306-2314. PubMed ID: 28493812
[TBL] [Abstract][Full Text] [Related]
22. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis.
Shipley WU; Thames HD; Sandler HM; Hanks GE; Zietman AL; Perez CA; Kuban DA; Hancock SL; Smith CD
JAMA; 1999 May; 281(17):1598-604. PubMed ID: 10235152
[TBL] [Abstract][Full Text] [Related]
23. Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.
Hoffman RM; Koyama T; Albertsen PC; Barry MJ; Daskivich TJ; Goodman M; Hamilton AS; Stanford JL; Stroup AM; Potosky AL; Penson DF
J Gen Intern Med; 2015 Jul; 30(7):924-34. PubMed ID: 25678374
[TBL] [Abstract][Full Text] [Related]
24. Survival associated with treatment vs observation of localized prostate cancer in elderly men.
Wong YN; Mitra N; Hudes G; Localio R; Schwartz JS; Wan F; Montagnet C; Armstrong K
JAMA; 2006 Dec; 296(22):2683-93. PubMed ID: 17164454
[TBL] [Abstract][Full Text] [Related]
25. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
26. Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States.
Fang F; Keating NL; Mucci LA; Adami HO; Stampfer MJ; Valdimarsdóttir U; Fall K
J Natl Cancer Inst; 2010 Mar; 102(5):307-14. PubMed ID: 20124521
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years.
Huang H; Muscatelli S; Naslund M; Badiyan SN; Kaiser A; Siddiqui MM
J Urol; 2019 Jan; 201(1):120-128. PubMed ID: 30059685
[TBL] [Abstract][Full Text] [Related]
28. Primary radiotherapy vs conservative management for localized prostate cancer--a population-based study.
Lu-Yao GL; Kim S; Moore DF; Shih W; Lin Y; DiPaola RS; Shen S; Zietman A; Yao SL
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):317-24. PubMed ID: 26101187
[TBL] [Abstract][Full Text] [Related]
29. Impact of comorbidity on survival among men with localized prostate cancer.
Albertsen PC; Moore DF; Shih W; Lin Y; Li H; Lu-Yao GL
J Clin Oncol; 2011 Apr; 29(10):1335-41. PubMed ID: 21357791
[TBL] [Abstract][Full Text] [Related]
30. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.
Bandini M; Mazzone E; Preisser F; Nazzani S; Zaffuto E; Marchioni M; Tian Z; Pompe RS; Tilki D; Graefen M; Shariat SF; Montorsi F; Saad F; Briganti A; Karakiewicz P
Eur Urol Oncol; 2018 Sep; 1(4):314-320. PubMed ID: 31100253
[TBL] [Abstract][Full Text] [Related]
31. Variation in Prostate-Specific Antigen Testing Rates and Prostate Cancer Treatments and Outcomes in a National 20-Year Cohort.
Bergengren O; Westerberg M; Holmberg L; Stattin P; Bill-Axelson A; Garmo H
JAMA Netw Open; 2021 May; 4(5):e219444. PubMed ID: 33999165
[TBL] [Abstract][Full Text] [Related]
32. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
Culp SH; Schellhammer PF; Williams MB
Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
[TBL] [Abstract][Full Text] [Related]
33. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis.
Brenner H; Arndt V
J Clin Oncol; 2005 Jan; 23(3):441-7. PubMed ID: 15572727
[TBL] [Abstract][Full Text] [Related]
34. Prostate cancer in Victoria in 1993: patterns of reported management.
Frydenberg M; Giles GG; Mameghan H; Thursfield VJ; Millar J; Wheelahan JB; Bolton DM; Syme RR
Med J Aust; 2000 Mar; 172(6):270-4. PubMed ID: 10860092
[TBL] [Abstract][Full Text] [Related]
35. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.
Welch HG; Fisher ES; Gottlieb DJ; Barry MJ
J Natl Cancer Inst; 2007 Sep; 99(18):1395-400. PubMed ID: 17848671
[TBL] [Abstract][Full Text] [Related]
36. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.
Zietman AL; Thakral H; Wilson L; Schellhammer P
J Urol; 2001 Nov; 166(5):1702-6. PubMed ID: 11586206
[TBL] [Abstract][Full Text] [Related]
37. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation.
Albertsen PC; Hanley JA; Penson DF; Fine J
J Urol; 2004 Jun; 171(6 Pt 1):2221-5. PubMed ID: 15126789
[TBL] [Abstract][Full Text] [Related]
38. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.
Kupelian PA; Buchsbaum JC; Patel C; Elshaikh M; Reddy CA; Zippe C; Klein EA
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):704-11. PubMed ID: 11849793
[TBL] [Abstract][Full Text] [Related]
39. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
40. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
